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Abstract
Background: Immune checkpoint inhibitors are changing the landscape of oncology treatment as they are
significantly improving treatment for multiple malignancies. Nivolumab, an anti-programmed death 1 antibody,
is a US Food and Drug Administration-approved treatment for melanoma, non-small cell lung cancer, and kidney
cancer but can result in a spectrum of autoimmune side effects. Adverse effects can occur within any organ system
in the body including the colon, lung, liver, endocrine systems, or kidneys.
Case presentation: A 70-year-old male with clear cell kidney cancer was admitted with acute kidney injury while
on nivolumab. A kidney biopsy revealed diffuse tubular injury and immune complex-mediated glomerulonephritis.
Electron microscopy of the specimen showed hump-like subepithelial deposits. Nivolumab was discontinued and
the patient was started on a high dose of steroids. After 5 months of systemic corticosteroids and hemodialysis,
the patient’s kidney function improved to his baseline level. Despite a prolonged interruption to treatment,
immunosuppressive therapy did not compromise the anticancer effects of nivolumab.
Conclusion: Immune-related adverse effects in the kidney can cause autoimmune glomerulonephritis as well as
tubulointerstitial injury. In the literature, immune-related nephritis generally responded well to systemic corticosteroid
treatment. Based on our experience, a prolonged course of a high dose of steroids and hemodialysis may be required
to achieve an adequate treatment effect.
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Background
The field of oncologic immunotherapy is expanding rap-
idly. Since its introduction into clinical application for
the treatment of melanoma [1, 2], immunotherapy has
been studied in numerous trials for other types of can-
cer. Although treatments appear promising, immune
checkpoint inhibition is associated with a unique cat-
egory of side effects, termed immune-related adverse
events (irAE) [3].
Programmed death 1 (PD1) is a transmembrane pro-
tein expressed on T cells, B cells, and natural killer cells.
It binds to PD ligand 1 (PDL1) on the cell surface of
tumor cells, inhibits cancer cell apoptosis, and down-
regulates the functions of T cells [4, 5]. Nivolumab is a
human immunoglobulin (Ig)G4 anti-PD1 monoclonal
antibody, designed to augment an immunologic reaction
against cancer cells. The medication is currently US
Food and Drug Administration-approved for patients
with advanced melanoma, non-small cell lung cancer,
and renal cell carcinoma. irAE caused by nivolumab can
affect any organ system including the lung, colon, liver,
endocrine, kidney, skin, and brain. Grade 3 or 4 kidney
injury was reported in 2% of the patients with renal cell
carcinoma who were treated with nivolumab (creatinine
>3 times above baseline or >4.0 mg/dL, or life-
threatening consequences requiring dialysis) [6].
Kidney injury can cause diverse sequelae and poten-
tially limit further oncologic treatment options, necessi-
tating close follow-up and treatment. In clinical practice,
irAE has been managed by treatment interruption and
systemic corticosteroids as the first line, and tumor
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necrosis factor inhibitors or cytotoxic immunosuppres-
sants as the second line [6].
In this report, we present a case of nivolumab-induced
glomerulonephritis successfully treated with prolonged
use of a high dose of steroids and hemodialysis.
Case presentation
History and initial presentation
The patient was a 70-year-old male with a past medical
history of oxygen-dependent chronic pulmonary ob-
structive disease, squamous cell carcinoma of the right
vocal cord (treated with definitive radiation therapy in
November 1998), and stage 3b chronic kidney disease
who was diagnosed with metastatic clear cell renal cell
carcinoma in January 2013. Other pertinent past medical
history included left renal vein thrombosis for which he
was taking enoxaparin. The patient had a history of
smoking (120 packs/year) but had quit smoking (120
packs/year) but had quit smoking in January 2013.
For the metastatic renal cell cancer, the patient was
started on pazopanib 600 mg daily in February 2013,
with a good initial response. However, medication was
discontinued in December 2013 because of disease
progression in the lungs and rib cage. He then began
treatment with nivolumab 3 mg/kg every 2 weeks in De-
cember 2013. His disease initially responded well to the
treatment. During the 10-month period while the patient
was on nivolumab, left and right kidney tumors de-
creased by 19 and 13%, respectively, and adrenal masses
decreased by 23% on both sides. He continued treatment
until October 27, 2014 when he was found to have acute
kidney injury (AKI), with a creatinine level of 10.08 mg/
dL. His serum creatinine level the month prior was
1.67 mg/dL. He was admitted for evaluation and
treatment for AKI. At the time of presentation, the pa-
tient had symptoms of generalized weakness, fatigue,
and loss of appetite. His temperature was 35.7 °C (tym-
panic), and his blood pressure and heart rate were 135/
70 mmHg and 79 beats/min, respectively. He showed a
1.7 kg weight gain over 1 month and there was the sug-
gestion of 1+ bilateral ankle edema on physical examin-
ation. There was no flank pain or costovertebral angle
tenderness.
Hospital course
Upon admission, a metabolic panel revealed sodium
135 mmol/L, potassium 3.8 mmol/L, chloride 95 mmol/
L, CO2 28 mmol/L, total protein 6.1 g/dL, blood urea ni-
trogen (BUN) 58 mg/dL, and creatinine 10.08 mg/dL.
Urinalysis was positive at >300 mg/dL for protein and 3+
for hemoglobin. On microscopic examination of urine,
there were too-numerous-to-count red blood cells, 3–5
white blood cells, and 1–3 granular casts observed under
high-power magnification. Fraction excretion of sodium
was 2.2%. Serum C3 and C4 levels were within normal
ranges. Hepatitis B surface antigen, hepatitis C antibody,
anti-nuclear antibody, anti-double strand DNA antibody,
glomerular basement membrane antibody, cytoplasmic
anti-neutrophil cytoplasmic antibody, and perinuclear
anti-neutrophil cytoplasmic antibody were all negative.
Ultrasound revealed solid masses in the interpolar region
of the right kidney and upper pole of the left kidney, rep-
resentative of his known renal cell carcinoma. Otherwise,
kidney sizes were within the normal range and there was
no evidence of hydronephrosis.
Biopsy of the right lower pole of the kidney was
performed on October 29, 2014. Light microscopic
examination demonstrated diffuse tubular injury with
vacuoles and immune complex-mediated glomerulo-
nephritis with cellular crescents and necrosis. There was
moderate interstitial inflammation with lymphocytes ob-
served. With immunofluorescence, there was diffuse
granular mesangial staining for IgA, C3, and kappa and
lambda light chains. The specimen was also sent for
electron microscopic examination. One glomerulus with
severe cellular crescents was selected for examination
and demonstrated several hump-like subepithelial de-
posits and no subendothelial deposits. There was partial
podocyte foot process effacement. Proximal tubules were
flattened with simplified tubular epithelium and shorter
microvilli. Pathologic examinations confirmed the final
diagnosis of acute toxic-type tubular injury and IgA-
dominant acute post-infectious glomerulonephritis. Pic-
tures of microscopic examinations are shown in Fig. 1.
Although there was the possibility of post-infectious
glomerulonephritis based on findings of glomerular de-
posits in the kidney biopsy, the patient did not show symp-
toms of streptococcal infection such as pharyngitis or a
rash prior to admission. The patient’s C3 level was normal
and he was not hypertensive. Based on patient’s previous
exposure to nivolumab and lymphocyte infiltration ob-
served in the biopsy, immunotherapy-induced kidney injury
was taken into consideration. Nivolumab was discontinued
and methylprednisolone administration 40 mg intraven-
ously twice a day was started. The following day, serum po-
tassium increased to 5.6 mmol/L, and creatinine and BUN
were elevated at 11.01 and 63 mg/dL, respectively. Neph-
rology was consulted and hemodialysis was initiated. Meth-
ylprednisolone was increased to 40 mg three times a day
(1 mg/kg/day). After the biopsy report, the patient was
started on pulse dose steroids, methylprednisolone 1 g
intravenously daily for 3 days, followed by methylpredniso-
lone 40 mg intravenously three times a day. The creatinine
level decreased after steroid treatment and hemodialysis.
Four days later, steroids were changed to oral prednisone
40 mg twice a day and the patient was discharged on ster-
oid treatment and outpatient hemodialysis. On the day of
discharge, his creatinine level was 8.80 mg/dL.
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Follow-up and outcome
One month after discharge, the patient was admitted
with a fever, rash, tachycardia, and leukocytosis, consist-
ent with systemic inflammatory response syndrome
(SIRS). The source of infection was unclear as blood and
urine cultures were negative. The patient had general-
ized patchy skin lesions with desquamation, most prom-
inent at the bilateral proximal arms and upper torso.
Biopsy of skin lesions was deferred, as they were thought
to be an irAE and already clinically improving with ster-
oid treatment. The patient was discharged after a short
course of intravenous antibiotics. The dose of prednis-
one was increased at this time. Another month after the
second hospitalization, the patient was re-admitted with
fever, tachycardia, and hypotension. Again, there was no
compelling source of infection identified after an exten-
sive diagnostic work up. During the third hospitalization
of 9 days, he received a stress dose of hydrocortisone
100 mg three times a day. Upon discharge, he resumed a
tapering course of steroids, starting with prednisone
60 mg daily. The patient tolerated the prolonged course
of oral steroids well with no apparent adverse effects.
Oral prednisone was stopped at the end of February
2015. In April 2015, his serum creatinine level was
1.81 mg/dL and BUN was 13 mg/dL. Hemodialysis was
discontinued on April 27, 2015. The last contact with
the patient was on March 30, 2016 and his kidney
function remained stable at the time. Change in
serum creatinine over the 6-month treatment period
is shown in Fig. 2.
While recovering from nivolumab toxicity, the patient
did not receive any treatment for renal cell carcinoma.
In spite of the prolonged systemic corticosteroid treat-
ment, anti-tumor activity seemed to continue as the tu-
mors in bilateral kidneys and adrenal glands decreased
in sizes for 18 months (left adrenal gland: 3.7 to 2.4 cm,
right adrenal gland: 7.0 to 5.8 cm, left kidney mass: 6.0
to 3.4 cm, right kidney mass: 7.0 to 5.8 cm; all measure-
ments in longest diameter). In March 2016, he was
started on axitinib 3 mg twice a day for symptomatic
disease progression (worsening of rib lesion).
Conclusions
irAE are encountered more frequently in daily oncologic
practice with the increased use of immune checkpoint
inhibitors. Immune checkpoint inhibition involves two
major transmembrane proteins, cytotoxic T-lymphocyte
antigen 4 and PD1. Nivolumab, a monoclonal anti-PD1
antibody, blocks T cell inhibition and stimulates the im-
munologic response towards cancer cells, but it may also
impair the self-tolerance of the immune system. This po-
tential side effect can occur in any organ of the body but
is known to predominately occur in the gastrointestinal
tract, lung, liver, and endocrine system [7].
In clinical trials of nivolumab or other anti-PD1 anti-
bodies, the renal system was not affected as frequently
as other organ systems. In a population of patients with
non-small cell lung cancer, seven of 287 patients (2.4%)
who were treated with nivolumab developed renal injury,
but all events were either grade 1 or 2 [8]. Among
a b
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Fig. 1 Microscopic examinations of kidney biopsy specimens. a and b Hematoxylin and eosin staining of the kidney biopsy specimen revealed
interstitial infiltrate with tubular injury (arrows), glomerulonephritis with cellular crescents (arrowhead), and mesangial proliferation (arrow).
c Immunofluorescence staining for IgA deposits. d Electron microscopic picture of subepithelial deposit (arrow)
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patients with melanoma treated with pembrolizumab
(anti-PD1 antibody), one of 277 patients (0.4%) experi-
enced nephritis with renal failure [9]. Another anti-PD1
antibody, lambrolizumab, was associated with renal fail-
ure in three of 135 patients (2%) with melanoma, with
two of these three patients having grade 3 or 4 adverse
events [10].
Table 1 summarizes case reports on irAE affecting the
kidney, identified in a review of the literature. Fadel et
al. reported a case of lupus nephritis that occurred after
use of ipilimumab and was resolved after steroid treat-
ment [11]. Six cases of ipilimumab-associated nephritis
were reported [12–15]. The articles generally reported
successful treatment of ipilimumab-associated nephritis
using systemic steroids. In addition, there were three
cases of AKI caused by anti-PD1 antibody, such as
nivolumab or pembrolizumab. Two patients who had
nivolumab-related kidney injury were successfully
treated with steroids [16], and one patient who devel-
oped pembrolizumab-related kidney injury showed
improvement of nephritis after steroid treatment [17].
Although alterations in immunologic self-tolerance
theoretically account for renal dysfunction, specific
mechanisms among existing case reports are diverse. Bi-
opsy results also varied. One patient was diagnosed with
lupus nephritis during treatment with ipilimumab [11].
Diagnosis was made based on the patient being positive
for anti-nuclear and anti-double-stranded DNA anti-
bodies. Electron microscopy confirmed the presence of
granular, electron-dense extra-membranous deposits.
Izzedine et al. reported two cases of acute interstitial
nephritis associated with ipilimumab [14]. In a more re-
cent case, reported by Thajudeen et al., a biopsy revealed
granulomas and interstitial infiltration with lymphocytes,
eosinophils, and plasma cells [15]. In the current case,
the biopsy revealed acute tubular injury and immune
complex-mediated glomerulonephritis.
Regardless of the etiology or biopsy results, patient’s
kidney functions generally improved after steroid treat-
ment. We found no case in our review of the literature
in which tumor necrosis factor inhibitors or cytotoxic
immunosuppressants were required. In some reviewed
Fig. 2 Serum creatinine changes over the 6-month treatment period
Jung et al. BMC Nephrology  (2016) 17:188 Page 4 of 6
cases, immunotherapy resumed after kidney function
improved. In the current case, nivolumab was perman-
ently discontinued and the patient continued on a
lengthy tapering course of steroids for approximately
4 months. Even after prolonged use of systemic cortico-
steroids and discontinuation of nivolumab, the immuno-
logic anti-tumor effect appeared to persist and the
tumors in his kidneys shrank in size. In the literature,
there was a case of a melanoma patient who experienced
continued tumor regression in spite of discontinuation
of ipilimumab and daily administration of systemic corti-
costeroids for irAE [18]. In another case of a patient
with melanoma treated with ipilimumab, both steroids
and infliximab were used for grade 3 colitis, and there
was no disease progression after approximately 3 years
[19]. In a clinical trial, corticosteroids for treatment of
irAE did not impact the clinical activity of ipilimumab in
advanced melanoma patients [20].
In the current case, the possibility of post-infectious
glomerulonephritis was raised based on glomerular deposits
in the kidney biopsy. However, the patient did not have
symptoms of pharyngitis or a skin infection prior to admis-
sion. Lack of hypertension and a normal C3 level were also
not consistent with post-infectious glomerulonephritis.
Autoimmune glomerular injury was determined as a major
component of the etiology in our case, based on the tem-
poral relationship between the use of nivolumab and the
onset of AKI. To the best of the authors’ knowledge, this is
the first case of nivolumab-associated glomerulonephritis
confirmed by light and electron microscopic findings.
The patient in our case was twice admitted with unex-
plained SIRS. Both hospitalizations occurred while on a
decreasing dose of prednisone. After extensive diagnostic
testing for infection, there was no clear source of SIRS.
Pyrexia has been reported as a side effect of immuno-
therapy in clinical trials, but our patient had severe SIRS
with hypotension requiring admission to the intensive
care unit. Although the potential relationship between
immunotherapy and SIRS is intriguing, more evidence is
required before a causal link can be established.
In summary, use of systemic corticosteroids has been
generally successful in achieving an optimal treatment
response for immunotherapy-associated renal dysfunc-
tion. Nivolumab manufacturer recommends 0.5–1 mg/
kg/day prednisone equivalents for grade 2 or 3 renal
dysfunction, and if no improvement occurs, 1–2 mg/kg/
day prednisone equivalents and discontinuation of nivo-
lumab. For life-threatening grade 4 renal dysfunction,
the recommendation is to start with 1–2 mg/kg/day
prednisone equivalents and permanently discontinue
nivolumab [6]. Based on our experience, a pulse dose of
steroids can be used for resistant renal dysfunction.
Although treatment responses may not be ostensible
initially, a presumptive decision of treatment failure
should be avoided. As in our case, patients may require
a prolonged course of systemic corticosteroids and
Table 1 Reports in the literature of immunotherapy-associated renal adverse events and treatment
Author No. of
patients
Age Gender Medication Cancer Kidney biopsy Treatment Outcome
Fadel et al.
[11] 2009
1 64 M Ipilimumab Melanoma Extra-membranous and mesangial
deposits of immunoglobulin









1 53 F Ipilimumab Mucosal Not available Steroids Resolved
2 72 F Ipilimumab Unknown
primary
Not available Steroids Resolved
Izzedine et al.
[14] 2014
1 72 M Ipilimumab Melanoma Interstitial inflammation and
poly-nuclear infiltration in glomerulus
Steroids Resolved
2 60 F Ipilimumab Melanoma Tubulointerstitial inflammation with












1 58 F Nivolumab Melanoma Not available Steroids Resolved
Hofmann et al.
[17] 2016





2 73 M Pembrolizumab Melanoma Not available Steroids Improved
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hemodialysis, and kidney function may improve months
later.
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